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A B S T R A C T
In this study we analyzed the contribution of genetic variability of the insertion/deletion (I/D) polymorphism of the
angiotensin-I converting enzyme (ACE) gene to the predisposition for coronary artery disease (CAD) in a group of pa-
tients with type 2 diabetes. The I/D ACE gene polymorphism was tested in 366 Caucasians with type 2 diabetes: 148
cases with CAD and 218 subjects with no history of CAD. We failed to demonstrate that the ACE DD genotype was a
risk factor for CAD in Caucasians with type 2 diabetes (OR 2.0, 95 % CI 0.9–4.7; p=0.1). In conclusion, we provide evi-
dence that the ACE deletion/deletion genotype is not a risk factor for CAD in Caucasians with type 2 diabetes.
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Introduction
The prevalence of type 2 diabetes has been rising
worldwide due to increasing obesity and decreasing
physical activity. In people with type 2 diabetes the
leading cause of death is coronary artery disease (CAD)1.
It is generally accepted that environmental and gene-
tical factors affect the pathogenesis of CAD2,3. In Slove-
nia several candidate genes for cardiovascular disorders
have been tested in the general population as well as in
diabetic patients3–8. Experimental studies and clinical
trials show that the renin angiotensin system affects
the pathogenesis of CAD and the prognosis of myocar-
dial infarction (MI)9,10.
The angiotensin-1 converting enzyme (ACE) dele-
tion/deletion (DD) genotype is associated with increased
serum concentrations of ACE, which results in enhan-
ced conversion of angiotensin I to II and degradation of
bradykinin11. In 1992 Cambien et al.12 showed that the
DD genotype of the ACE gene polymorphism is a potent
risk factor for MI. Many reports about the role of DD ge-
notype in pathogenesis of CAD and MI have been pub-
lished since, but only few have so far been performed on
patients with type 2 diabetes13–19. In previous studies on
Slovene population the DD genotype was found to be an
independent risk factor for premature MI in general
population20,21.
The aim of this study was to determine whether the
ACE DD genotype is a risk factor for CAD in a group of
Caucasians with type 2 diabetes.
Materials and Methods
The study population of this cross-sectional analysis
consisted of 366 diabetic subjects with type 2 diabetes
duration of more than 10 years. In CAD group (148
cases) there were 110 cases with a history of MI (the di-
agnosis of MI was made according to the criteria of
World Health Organization) and 38 cases with angina
pectoris confirmed with either abnormal stress testing
or abnormal perfusion scan. The control group consisted
of 218 diabetics with no history of CAD, no signs of
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ischemic changes on electrocardiogram and no ischemic
changes during submaximal stress testing. The patients
and control subjects came from independent families.
The data and blood samples of age-matched controls
were obtained from general practitioners. The controls
did not have a history of angina pectoris or MI, and they
had normal electrocardiogram. All the subjects enrolled
in the study were Slovenes. The research protocol was
approved by the National Medical Ethics Committee.
After informed consent was obtained from the patients
and control subjects, a detailed interview was made.
The physician interviewed each patient about the coro-
nary risk factors (cigarette smoking, arterial hyperten-
sion, body weight and height). Smoking habit was de-
fined as a daily intake of more than 5 cigarettes. Arte-
rial hypertension was defined as binary variable. Arte-
rial hypertension was defined as systolic blood pressure
higher than 140 mm Hg, diastolic blood pressure higher
than 90 mm Hg, or both, at repeated measurements, or
current use of antihypertensive agents for confirmed di-
agnosis of arterial hypertension. Patients were classi-
fied as having type 2 diabetes according to current ADA
criteria for the diagnosis and classification of diabetes22.
Total cholesterol, low density lipoproteins (LDL),
high density lipoproteins (HDL) and triglycerides were
determined by standard biochemical methods.
I/D polymorphism of ACE gene was evaluated as de-
scribed previously20. Genotyping was performed by two
researchers (MG, AM@), blinded to the CAD status of
the patients.
Differences in mean values were analyzed by Stu-
dent t-test. Chi-square test was used to compare dis-
crete variables. Statistical analysis was performed us-
ing the SPSS program for Windows 2000 version 11
(SPSS Inc., Illinois). Statistical significance was set at
p<0.05. Logistic regression analysis was performed to
assess the independent role of the ACE-DD genotype
and other variables, including sex, smoking, duration of
diabetes, LDL cholesterol level, HDL cholesterol level.
Results
The ACE genotype distributions in cases and con-
trols were compatible with Hardy-Weinberg expecta-
tions (Table 1; ACE cases: p=0.93, 2=0.007; ACE con-
trols: p=0.69, 2=0.15). The characteristics of the cases
and control subjects are listed in Table 2 (91.5 % of cases
were males). A higher incidence of cigarette smoking
(45.9 % vs. 14.2 %; p0.001) was registered in the CAD
than in the control group. The cases had a higher LDL
cholesterol level (3.6±1.2 mmol/l vs. 3.2±1.0, p = 0.002),
higher BMI (28.9±3.7 vs. 28.0±4.6; p=0.04) and longer
duration of diabetes (22.2±6.9 vs. 17.5±8.3; p=0.001)
than the controls (Table 2). There were no significant
differences in the incidence of hypertension, total cho-
lesterol level, HDL cholesterol level and triglycerides
level between the cases and control subjects (Table 2).
Univariate analysis (Table 2) demonstrated smoking
and male sex to be associated with a 4.9-fold (95%
CI=2.9–8.2; p<0.001) and a 2.3-fold risk of CAD (95%
CI=1.5–3.6; p<0.001), respectively.
Multiple logistic regression analysis of the data (Ta-
ble 3) showed that the ACE DD genotype was not an in-
dependent risk factor for MI in type 2 diabetes (OR=1.4;
95% CI=0.8–2.3; p=0.23).
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TABLE 1
DISTRIBUTION OF ACE I/D GENOTYPES AMONG
CAD PATIENTS AND CONTROLS (p=0.3, 2=2.1)
Variable CAD patients (%) Controls (%)
DD genotype 49 (32.9%) 60 (27.5%)1
ID genotype 72 (48.3%) 104 (47.7%)
II genotype 28 (18.8%) 54 (24.8%)
1 Odds ratio (DD genotype vs. ID genotype + II genotype) =
1.3; 95% CI=0.8–2.0; p=0.3)
TABLE 3
ADJUSTED ODDS RATIOS FOR CARDIOVASCULAR RISK
FACTORS IN CAD PATIENTS
Risk factors OR (95% CI)1 p
Diabetes duration 0.95 (0.9–1.0) 0.07
DD genotype2 2.0 (0.9–4.7) 0.1
Smoking 1.1 (0.4–3.5) 0.8
Male sex 1.1 (0.4–2.6) 0.9
HDL cholesterol 1.2 (0.4–4.0) 0.8
LDL cholesterol 1.4 (0.9–2.2) 0.2
1 Odds ratio (95% confidence interval)
2ACE insertion/deletion gene polymorphism
TABLE 2









Age (years) 58.6±11.3 65.4±9.9 <0.001
Male sex 97 (65.1) 99 (45.4) <0.001
BMI (kg/m2) 28.9±3.7 28.0±4.6 0.04
Arterial hypertension 101 (67.8) 141 (64.7) 0.5
Smoking habit 68 (45.6) 31 (14.2) <0.001
Diabetes duration (years) 22.2±6.9 17.5±8.3 <0.001
Total cholesterol (mmol/l) 5.7±1.3 5.5±1.4 0.1
HDL cholesterol (mmol/l) 1.1±0.3 1.2±0.3 0.07
LDL cholesterol (mmol/l) 3.6±1.2 3.2±1.0 0.002
Triglycerides (mmol/l) 2.3±1.3 2.6±1.8 0.2
Values are means ± SD
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Discussion
In the study we failed to demonstrate that the ACE
DD genotype was a risk factor for CAD in Caucasians
with type 2 diabetes.
In a mixed population (196 males+170 females) of
366 patients with type 2 diabetes we failed to demon-
strate an association between the ACE DD genotype
and an increased risk of CAD (OR=1.3; 95% CI=0.8–2.0;
p=0.3). A separate analysis by sex showed an associa-
tion between the ACE DD genotype and CAD in females
(OR=2.6; 95% CI=1.3–5.2; p=0.007), but not in males
(OR=0.8; 95% CI=0.4–1.4; p=0.4). In previous study the
ACE DD genotype was an independent risk factor for
premature MI in the general population (OR= 2; 95% CI
1.1–3.7; p=0.01)20.
Only few studies have been performed so far on pa-
tients with type 2 diabetes, however, the results were
inconsistent13–16. Several studies including meta-analy-
sis published by Samani et al.17 demonstrated an associ-
ation between the ACE DD genotype and MI and CHD.
However, Agerholm-Larsen et al.11 have recently re-
ported a difference in the effect of the ACE DD genotype
on CAD, MI, or ischemic cerebrovascular disease be-
tween small and large studies: risk of MI and CAD was
increased by 47 % and 29 %, respectively, for DD versus
ID and II genotypes in small studies but not in large
studies11. Case control studies may suffer from several
biases, which may lead to false positive and false nega-
tive results23,24. In association studies the survival bias
cannot be avoided. It is possible that early mortality in
CAD patients with type 2 diabetes is due to the ACE
gene and that this could lead to an underestimation of
the role of the DD genotype in patients with CAD in our
study. Furthermore, a higher percentage of women in
our study compared to the study of Ruiz et al.16 might
also be of importance, since CAD mortality associated
with diabetes is greater for women than for men16,25–27.
In our study longer duration of diabetes was demon-
strated in the CAD group compared to the control group.
Longer duration of diabetes was demonstrated to be an
important predictor of total mortality and the mortality
due to CAD among women and men with type 2 diabe-
tes28,29.
In conclusion, the ACE DD genotype is not a risk fac-
tor for CAD in Caucasians with type 2 diabetes.
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DELECIJA/DELECIJA GENOTIP ZA ANGIOTENZIN I KONVERTAZU NIJE POVEZAN
S KORONARNOM BOLESTI SRCA KOD BIJELACA S DIJABETESOM TIPA 2
S A @ E T A K
U ovoj studiji analiziran je doprinos genetske varijabilnosti insercije/delecije polimorfizma gena za angiotenzin-I
konvertazu na predispoziciju za koronarnu bolest srca u grupi pacijenata s dijabetesom tipa 2. Varijabilnost insercije/
delecije gena za angiotenzin-I konvertazu je testirana na 366 bijelaca s dijabetesom tipa 2: 148 ih je imalo koronarnu
bolest srca, dok ih 218 nije imalo koronarnu bolest srca. Nije dokazano da je delecija/delecija genotip za angiotenzin-I
konvertazu rizi~ni faktor za koronarnu bolest srca kod bijelaca s dijabetesom tipa 2 (OR 2.0, 95% CI 0,9–4,7; p=0,1).
Kao zaklju~ak, pru`amo dokaz da delecija/delecija genotip za angiotenzin-I konvertazu nije rizi~ni faktor za koro-
narnu bolest srca kod bijelaca s dijabetesom tipa 2.
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